alendronate has been researched along with Brittle Bone Disease in 39 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "25OHD = 25-hydroxyvitamin D ALN = alendronate ALP = alkaline phosphatase β-CTX = cross-linked C-telopeptide of type I collagen BMD = bone mineral density BP = bisphosphonate FN = femoral neck LS = lumbar spine OI = osteogenesis imperfecta SAE = severe adverse event ZOL = zoledronic acid." | 9.27 | ZOLEDRONIC ACID VERSUS ALENDRONATE IN THE TREATMENT OF CHILDREN WITH OSTEOGENESIS IMPERFECTA: A 2-YEAR CLINICAL STUDY. ( Jiang, Y; Li, L; Liu, Y; Lv, F; Song, Y; Wang, O; Xia, W; Xing, X; Xu, X, 2018) |
| "To explore the clinical efficacy and safety of oral alendronate in children with osteogenesis imperfecta (OI)." | 9.16 | [Clinical study of oral alendronate in the treatment of pediatric osteogenesis imperfecta]. ( Cai, QX; Chen, Q; Gu, XF; Qiu, WJ; Wang, XL; Wei, SS; Ye, J; Zhao, L, 2012) |
| "A 3-year, randomized, double-blind, placebo-controlled trial evaluated the effect of oral alendronate on the BMD of 64 adult patients with osteogenesis imperfecta." | 9.12 | Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. ( Arlot, M; Charrin, JE; Chevrel, G; Duboeuf, F; Fontanges, E; Garnero, P; Lina-Granade, G; Meunier, PJ; Raynal, C; Schott, AM, 2006) |
| "The purpose of this study was to evaluate the effects of alendronate on orthodontic tooth movement (OTM) and bone modelling/remodelling in an osteogenesis imperfecta (OI) mice model." | 8.31 | How does alendronate affect orthodontic tooth movement in osteogenesis imperfecta: an in vivo study on a mice model. ( Ahmida, A; Chen, PJ; Kalajzic, Z; Mehta, S; Wang, K; Yadav, S; Zhichao, F, 2023) |
| "Alendronate (Aln) has been the first-line drug for osteogenesis imperfecta (OI), while the comparable efficacy of Aln and strontium ranelate (SrR) remains unclear." | 8.02 | Comparable Effects of Strontium Ranelate and Alendronate Treatment on Fracture Reduction in a Mouse Model of Osteogenesis Imperfecta. ( Chen, R; He, H; Ma, C; Shi, C; Sun, B; Wu, H; Zhang, Y, 2021) |
| "We report a direct comparison of receptor activator of nuclear factor kappa B ligand (RANKL) inhibition (RANK-Fc) with bisphosphonate treatment (alendronate, ALN) from infancy through early adulthood in a mouse model of osteogenesis imperfecta." | 7.78 | Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta. ( Bargman, R; Boskey, AL; DiCarlo, E; Pleshko, N; Posham, R; Raggio, C, 2012) |
| "Alendronate has positively influenced quality of life in paediatric patients with osteogenesis imperfecta." | 7.73 | Effect of alendronate therapy in children with osteogenesis imperfecta. ( Kutílek, S; Pikner, R; Vyskocil, V, 2005) |
| "A case of osteogenesis imperfecta (OI), which was successfully treated with alendronate is reported." | 7.72 | Effect of treatment with alendronate in osteogenesis imperfecta type I: a case report. ( Iwamoto, J; Sato, Y; Takeda, T, 2004) |
| "Alendronate (ALN) is a bisphosphonate compound that can be administered orally and has potential use in pediatric osteoporotic conditions." | 6.71 | Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I. ( Denker, AE; Deutsch, P; Glorieux, FH; Kline, W; Larson, P; Maes, A; Mao, C; Porras, A; Rauch, F; Shugarts, S; Travers, R; Ward, LM, 2005) |
| " However, bisphosphonates reside in the skeleton for many years and long-term administration may impact bone material quality." | 5.39 | Fracture healing with alendronate treatment in the Brtl/+ mouse model of osteogenesis imperfecta. ( Begun, DL; Caird, MS; Goldstein, SA; Kozloff, KM; Marini, JC; McElderry, JD; Meganck, JA; Morris, MD; Swick, A, 2013) |
| " The high dosage of alendronate increased overall growth plate height, particularly within the hypertrophic zone, which suggests a failure of vascular invasion-induced apoptosis in the hypertrophic cells." | 5.32 | Alendronate affects long bone length and growth plate morphology in the oim mouse model for Osteogenesis Imperfecta. ( Evans, KD; Lau, ST; Martin, RB; Oberbauer, AM, 2003) |
| "Alendronate was administered to 6-week-old mice during a period of active growth at a dosage of 73 microg alendronate/kg/day for the first 4 weeks and 26 microg alendronate/kg/day for the next 4 weeks." | 5.31 | A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta. ( Boskey, AL; Camacho, NP; Doty, SB; Ilg, WA; Raggio, CL; Root, L; Toledano, TR; Zraick, V, 2001) |
| "25OHD = 25-hydroxyvitamin D ALN = alendronate ALP = alkaline phosphatase β-CTX = cross-linked C-telopeptide of type I collagen BMD = bone mineral density BP = bisphosphonate FN = femoral neck LS = lumbar spine OI = osteogenesis imperfecta SAE = severe adverse event ZOL = zoledronic acid." | 5.27 | ZOLEDRONIC ACID VERSUS ALENDRONATE IN THE TREATMENT OF CHILDREN WITH OSTEOGENESIS IMPERFECTA: A 2-YEAR CLINICAL STUDY. ( Jiang, Y; Li, L; Liu, Y; Lv, F; Song, Y; Wang, O; Xia, W; Xing, X; Xu, X, 2018) |
| "25OHD = 25-hydroxyvitamin D ALN = alendronate ALP = alkaline phosphatase BMD = bone mineral density BMI = body mass index BP = bisphosphonate β-CTX = cross-linked C-telopeptide of type I collagen FN = femoral neck LS = lumbar spine OI = osteogenesis imperfecta RCT = randomized controlled trial TH = total hip ZOL = zoledronic acid." | 5.22 | THE CLINICAL CHARACTERISTICS AND EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA. ( Jiang, Y; Li, M; Liu, Y; Lv, F; Ma, DD; Wang, JY; Wang, O; Xia, WB; Xing, XP; Xu, XJ; Yu, W, 2016) |
| "To explore the clinical efficacy and safety of oral alendronate in children with osteogenesis imperfecta (OI)." | 5.16 | [Clinical study of oral alendronate in the treatment of pediatric osteogenesis imperfecta]. ( Cai, QX; Chen, Q; Gu, XF; Qiu, WJ; Wang, XL; Wei, SS; Ye, J; Zhao, L, 2012) |
| "A 3-year, randomized, double-blind, placebo-controlled trial evaluated the effect of oral alendronate on the BMD of 64 adult patients with osteogenesis imperfecta." | 5.12 | Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. ( Arlot, M; Charrin, JE; Chevrel, G; Duboeuf, F; Fontanges, E; Garnero, P; Lina-Granade, G; Meunier, PJ; Raynal, C; Schott, AM, 2006) |
| "The purpose of this study was to evaluate the effects of alendronate on orthodontic tooth movement (OTM) and bone modelling/remodelling in an osteogenesis imperfecta (OI) mice model." | 4.31 | How does alendronate affect orthodontic tooth movement in osteogenesis imperfecta: an in vivo study on a mice model. ( Ahmida, A; Chen, PJ; Kalajzic, Z; Mehta, S; Wang, K; Yadav, S; Zhichao, F, 2023) |
| "Alendronate (Aln) has been the first-line drug for osteogenesis imperfecta (OI), while the comparable efficacy of Aln and strontium ranelate (SrR) remains unclear." | 4.02 | Comparable Effects of Strontium Ranelate and Alendronate Treatment on Fracture Reduction in a Mouse Model of Osteogenesis Imperfecta. ( Chen, R; He, H; Ma, C; Shi, C; Sun, B; Wu, H; Zhang, Y, 2021) |
| "We report a direct comparison of receptor activator of nuclear factor kappa B ligand (RANKL) inhibition (RANK-Fc) with bisphosphonate treatment (alendronate, ALN) from infancy through early adulthood in a mouse model of osteogenesis imperfecta." | 3.78 | Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta. ( Bargman, R; Boskey, AL; DiCarlo, E; Pleshko, N; Posham, R; Raggio, C, 2012) |
| "5 months of treatment, oral alendronate is associated with a lower fracture rate, improvement in BMD and a decrease in hypercalciuria." | 3.74 | Oral bisphosphonate treatment for osteogenesis imperfecta--an Indian perspective. ( Johari, A; Shah, I, 2007) |
| "Alendronate has positively influenced quality of life in paediatric patients with osteogenesis imperfecta." | 3.73 | Effect of alendronate therapy in children with osteogenesis imperfecta. ( Kutílek, S; Pikner, R; Vyskocil, V, 2005) |
| " In the current study, FT-IRM and FT-IRIS were used to characterize bone mineralization in a mouse model of osteogenesis imperfecta (OI) after treatment with the bisphosphonate alendronate (ALN)." | 3.72 | Fourier transform infrared imaging spectroscopy (FT-IRIS) of mineralization in bisphosphonate-treated oim/oim mice. ( Camacho, NP; Carroll, P; Raggio, CL, 2003) |
| "The complex treatment of Osteogenesis imperfecta should include alendronate and calcitriol to decrease fractures and improve bone mineral density." | 3.72 | Treatment of children with Osteogenesis imperfecta in Estonia. ( Haviko, T; Maasalu, K; Märtson, A, 2003) |
| "A case of osteogenesis imperfecta (OI), which was successfully treated with alendronate is reported." | 3.72 | Effect of treatment with alendronate in osteogenesis imperfecta type I: a case report. ( Iwamoto, J; Sato, Y; Takeda, T, 2004) |
| "Pamidronate-treated type III/IV and oral bisphosphonate-treated type I patients showed significant increases in total-hip BMD (0." | 2.75 | Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta. ( Gillen, C; Nunes, M; Shapiro, JR; Thompson, CB; Wu, Y, 2010) |
| "Alendronate (ALN) is a bisphosphonate compound that can be administered orally and has potential use in pediatric osteoporotic conditions." | 2.71 | Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I. ( Denker, AE; Deutsch, P; Glorieux, FH; Kline, W; Larson, P; Maes, A; Mao, C; Porras, A; Rauch, F; Shugarts, S; Travers, R; Ward, LM, 2005) |
| "Pain is one of the most common symptoms in children and young people (CYP) with life-limiting conditions (LLCs) which include a wide range of diagnoses including cancer." | 2.52 | Pharmacological interventions for pain in children and adolescents with life-limiting conditions. ( Beecham, E; Bluebond-Langner, M; Candy, B; Howard, R; Jones, L; Laddie, J; McCulloch, R; Rees, H; Vickerstaff, V, 2015) |
| "Zoledronic acid has undergone international multicentric clinical trials to examine efficiency and long-term side effects including osteonecrosis of the jaw." | 2.45 | [Bisphosphonates and other new therapeutic agents for the treatmednt of osteogenesis imperfecta]. ( Yamashita, S, 2009) |
| "They are used in the treatment of Paget's disease of bone, hypercalcaemia and osteolytic bone disease of malignancy, primary and secondary hyperparathyroidism, and in osteoporosis." | 2.41 | Bisphosphonates: an overview with special reference to alendronate. ( Vasikaran, SD, 2001) |
| "We report a rare association of amniotic bands with osteogenesis imperfecta in a child." | 1.42 | A rare combination of amniotic constriction band with osteogenesis imperfecta. ( Shah, H; Shah, KH, 2015) |
| " However, bisphosphonates reside in the skeleton for many years and long-term administration may impact bone material quality." | 1.39 | Fracture healing with alendronate treatment in the Brtl/+ mouse model of osteogenesis imperfecta. ( Begun, DL; Caird, MS; Goldstein, SA; Kozloff, KM; Marini, JC; McElderry, JD; Meganck, JA; Morris, MD; Swick, A, 2013) |
| " The high dosage of alendronate increased overall growth plate height, particularly within the hypertrophic zone, which suggests a failure of vascular invasion-induced apoptosis in the hypertrophic cells." | 1.32 | Alendronate affects long bone length and growth plate morphology in the oim mouse model for Osteogenesis Imperfecta. ( Evans, KD; Lau, ST; Martin, RB; Oberbauer, AM, 2003) |
| "Alendronate was administered to 6-week-old mice during a period of active growth at a dosage of 73 microg alendronate/kg/day for the first 4 weeks and 26 microg alendronate/kg/day for the next 4 weeks." | 1.31 | A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta. ( Boskey, AL; Camacho, NP; Doty, SB; Ilg, WA; Raggio, CL; Root, L; Toledano, TR; Zraick, V, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 19 (48.72) | 29.6817 |
| 2010's | 15 (38.46) | 24.3611 |
| 2020's | 5 (12.82) | 2.80 |
| Authors | Studies |
|---|---|
| Shanas, N | 1 |
| Querido, W | 1 |
| Oswald, J | 1 |
| Jepsen, K | 1 |
| Carter, E | 1 |
| Raggio, C | 2 |
| Pleshko, N | 3 |
| Mehta, S | 1 |
| Wang, K | 1 |
| Chen, PJ | 1 |
| Zhichao, F | 1 |
| Ahmida, A | 1 |
| Kalajzic, Z | 1 |
| Yadav, S | 1 |
| Harada, D | 1 |
| Kashiwagi, H | 1 |
| Ueyama, K | 1 |
| Oriyama, K | 1 |
| Hanioka, Y | 1 |
| Sakamoto, N | 1 |
| Kondo, K | 1 |
| Kishimoto, K | 1 |
| Izui, M | 1 |
| Nagamatsu, Y | 1 |
| Yamada, H | 1 |
| Tanaka, H | 1 |
| Namba, N | 1 |
| Seino, Y | 1 |
| Shi, C | 1 |
| Sun, B | 1 |
| Ma, C | 1 |
| Wu, H | 1 |
| Chen, R | 1 |
| He, H | 1 |
| Zhang, Y | 1 |
| Xi, L | 1 |
| Lv, S | 1 |
| Zhang, H | 1 |
| Zhang, ZL | 1 |
| Lv, F | 3 |
| Liu, Y | 3 |
| Xu, X | 2 |
| Song, Y | 1 |
| Li, L | 1 |
| Jiang, Y | 3 |
| Wang, O | 3 |
| Xia, W | 2 |
| Xing, X | 2 |
| Tomecka, MJ | 1 |
| Ethiraj, LP | 1 |
| Sánchez, LM | 1 |
| Roehl, HH | 1 |
| Carney, TJ | 1 |
| Meganck, JA | 1 |
| Begun, DL | 1 |
| McElderry, JD | 1 |
| Swick, A | 1 |
| Kozloff, KM | 2 |
| Goldstein, SA | 2 |
| Morris, MD | 1 |
| Marini, JC | 2 |
| Caird, MS | 1 |
| Beecham, E | 1 |
| Candy, B | 1 |
| Howard, R | 1 |
| McCulloch, R | 1 |
| Laddie, J | 1 |
| Rees, H | 1 |
| Vickerstaff, V | 1 |
| Bluebond-Langner, M | 1 |
| Jones, L | 1 |
| Boskey, AL | 5 |
| Marino, J | 1 |
| Spevak, L | 1 |
| Doty, S | 1 |
| Carter, EM | 1 |
| Raggio, CL | 6 |
| Shah, KH | 1 |
| Shah, H | 1 |
| Wang, J | 1 |
| Ma, D | 1 |
| Yu, W | 2 |
| Li, M | 2 |
| Xu, XJ | 1 |
| Ma, DD | 1 |
| Wang, JY | 1 |
| Xia, WB | 1 |
| Xing, XP | 1 |
| Uveges, TE | 1 |
| Ty, JM | 1 |
| Ledgard, F | 1 |
| Gronowicz, G | 1 |
| Yamashita, S | 2 |
| Gallego, L | 1 |
| Junquera, L | 1 |
| Pelaz, A | 1 |
| Costilla, S | 1 |
| Shapiro, JR | 1 |
| Thompson, CB | 1 |
| Wu, Y | 1 |
| Nunes, M | 1 |
| Gillen, C | 1 |
| Ward, LM | 2 |
| Rauch, F | 2 |
| Whyte, MP | 1 |
| D'Astous, J | 1 |
| Gates, PE | 1 |
| Grogan, D | 1 |
| Lester, EL | 1 |
| McCall, RE | 1 |
| Pressly, TA | 1 |
| Sanders, JO | 1 |
| Smith, PA | 1 |
| Steiner, RD | 1 |
| Sullivan, E | 1 |
| Tyerman, G | 1 |
| Smith-Wright, DL | 1 |
| Verbruggen, N | 1 |
| Heyden, N | 1 |
| Lombardi, A | 1 |
| Glorieux, FH | 2 |
| Bargman, R | 1 |
| Posham, R | 1 |
| DiCarlo, E | 1 |
| Wei, SS | 1 |
| Cai, QX | 1 |
| Qiu, WJ | 1 |
| Zhao, L | 1 |
| Ye, J | 1 |
| Wang, XL | 1 |
| Chen, Q | 1 |
| Gu, XF | 1 |
| Meier, RP | 1 |
| Ing Lorenzini, K | 1 |
| Uebelhart, B | 1 |
| Stern, R | 1 |
| Peter, RE | 1 |
| Rizzoli, R | 1 |
| McCarthy, EA | 1 |
| Hossack, MD | 1 |
| Miller, EA | 1 |
| Jain, S | 1 |
| Camacho, NP | 4 |
| Carroll, P | 1 |
| Evans, KD | 1 |
| Lau, ST | 1 |
| Oberbauer, AM | 1 |
| Martin, RB | 1 |
| Maasalu, K | 1 |
| Haviko, T | 1 |
| Märtson, A | 1 |
| Iwamoto, J | 1 |
| Takeda, T | 1 |
| Sato, Y | 1 |
| Misof, BM | 1 |
| Roschger, P | 1 |
| Baldini, T | 1 |
| Zraick, V | 2 |
| Root, L | 2 |
| Klaushofer, K | 1 |
| Fratzl, P | 1 |
| Dimeglio, LA | 2 |
| Ford, L | 1 |
| McClintock, C | 1 |
| Peacock, M | 2 |
| Denker, AE | 1 |
| Porras, A | 1 |
| Shugarts, S | 1 |
| Kline, W | 1 |
| Travers, R | 1 |
| Mao, C | 1 |
| Maes, A | 1 |
| Larson, P | 1 |
| Deutsch, P | 1 |
| Vyskocil, V | 1 |
| Pikner, R | 1 |
| Kutílek, S | 1 |
| Unal, E | 1 |
| Abaci, A | 1 |
| Bober, E | 1 |
| Buyukgebiz, A | 1 |
| Chevrel, G | 1 |
| Schott, AM | 1 |
| Fontanges, E | 1 |
| Charrin, JE | 1 |
| Lina-Granade, G | 1 |
| Duboeuf, F | 1 |
| Garnero, P | 1 |
| Arlot, M | 1 |
| Raynal, C | 1 |
| Meunier, PJ | 1 |
| Madenci, E | 1 |
| Yilmaz, K | 1 |
| Yilmaz, M | 1 |
| Coskun, Y | 1 |
| Shah, I | 1 |
| Johari, A | 1 |
| Damiani, D | 1 |
| Doty, SB | 1 |
| Ilg, WA | 1 |
| Toledano, TR | 1 |
| Vasikaran, SD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation[NCT02074631] | Phase 2 | 80 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for alendronate and Brittle Bone Disease
| Article | Year |
|---|---|
Pharmacological interventions for pain in children and adolescents with life-limiting conditions.
Topics: Adolescent; Alendronate; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Child; Child, Preschool | 2015 |
[Bisphosphonates and other new therapeutic agents for the treatmednt of osteogenesis imperfecta].
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Ag | 2009 |
[Bone and joint diseases in children. Bisphosphonates in osteogenesis imperfecta].
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Child; Child, Preschool; Diphos | 2010 |
Bisphosphonates: an overview with special reference to alendronate.
Topics: Alendronate; Bone Density; Bone Neoplasms; Bone Resorption; Calcium; Clinical Trials as Topic; Dipho | 2001 |
11 trials available for alendronate and Brittle Bone Disease
| Article | Year |
|---|---|
Monthly intravenous alendronate treatment can maintain bone strength in osteogenesis imperfecta patients following cyclical pamidronate treatment.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Child; Child, Preschool; Drug Administr | 2020 |
ZOLEDRONIC ACID VERSUS ALENDRONATE IN THE TREATMENT OF CHILDREN WITH OSTEOGENESIS IMPERFECTA: A 2-YEAR CLINICAL STUDY.
Topics: Adolescent; Alendronate; Bone Density; Child; Child, Preschool; Diphosphonates; Female; Follow-Up St | 2018 |
THE CLINICAL CHARACTERISTICS AND EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA.
Topics: Absorptiometry, Photon; Adolescent; Adult; Alendronate; Biomarkers; Bone Density; Bone Density Conse | 2016 |
Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
Topics: Administration, Oral; Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Cohort Stu | 2010 |
Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study.
Topics: Adolescent; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Child; Chil | 2011 |
[Clinical study of oral alendronate in the treatment of pediatric osteogenesis imperfecta].
Topics: Adolescent; Alendronate; Bone Density Conservation Agents; Child; Child, Preschool; Female; Humans; | 2012 |
A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta.
Topics: Administration, Oral; Adolescent; Age Factors; Alendronate; Anti-Inflammatory Agents; Bone Density; | 2005 |
Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I.
Topics: Adolescent; Alendronate; Biological Availability; Child; Child, Preschool; Cross-Over Studies; Femal | 2005 |
Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.
Topics: Administration, Oral; Alendronate; Biomarkers; Bone Density Conservation Agents; Bone Remodeling; Ch | 2006 |
Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial.
Topics: Absorptiometry, Photon; Administration, Oral; Adult; Alendronate; Biomarkers; Bone Density; Bone Den | 2006 |
Alendronate treatment in osteogenesis imperfecta.
Topics: Absorptiometry, Photon; Alendronate; Alkaline Phosphatase; Bone Density; Bone Density Conservation A | 2006 |
24 other studies available for alendronate and Brittle Bone Disease
| Article | Year |
|---|---|
Infrared Spectroscopy-Determined Bone Compositional Changes Associated with Anti-Resorptive Treatment of the
Topics: Alendronate; Animals; Bone and Bones; Disease Models, Animal; Mice; Minerals; Osteogenesis Imperfect | 2022 |
How does alendronate affect orthodontic tooth movement in osteogenesis imperfecta: an in vivo study on a mice model.
Topics: Alendronate; Animals; Bone Remodeling; Collagen; Disease Models, Animal; Female; Male; Mice; Osteocl | 2023 |
Comparable Effects of Strontium Ranelate and Alendronate Treatment on Fracture Reduction in a Mouse Model of Osteogenesis Imperfecta.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Resorption; Disease Model | 2021 |
Novel mutations in BMP1 result in a patient with autosomal recessive osteogenesis imperfecta.
Topics: Alendronate; Bone Density Conservation Agents; Bone Morphogenetic Protein 1; Child; Female; Homozygo | 2021 |
Clinical pathologies of bone fracture modelled in zebrafish.
Topics: Alendronate; Animal Fins; Animals; Bony Callus; Diphosphonates; Disease Models, Animal; Fracture Hea | 2019 |
Fracture healing with alendronate treatment in the Brtl/+ mouse model of osteogenesis imperfecta.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bony Callus; Densitometry; Disease Models, Animal; Fe | 2013 |
Are Changes in Composition in Response to Treatment of a Mouse Model of Osteogenesis Imperfecta Sex-dependent?
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Resorption; Collagen; Dis | 2015 |
A rare combination of amniotic constriction band with osteogenesis imperfecta.
Topics: Alendronate; Amniotic Band Syndrome; Bone Density Conservation Agents; Bone Diseases, Metabolic; Chi | 2015 |
EFFECTS OF LONG-TERM ALENDRONATE TREATMENT ON A LARGE SAMPLE OF PEDIATRIC PATIENTS WITH OSTEOGENESIS IMPERFECTA.
Topics: Adolescent; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling | 2016 |
Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone Density; Calcification, Physiologic; Cartilage; | 2009 |
Pathological mandibular fracture after simple molar extraction in a patient with osteogenesis imperfecta treated with alendronate.
Topics: Adult; Alendronate; Diphosphonates; Fractures, Spontaneous; Humans; Male; Mandibular Fractures; Mola | 2010 |
Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta.
Topics: Acid Phosphatase; Alendronate; Animals; Biomechanical Phenomena; Bone Density; Bone Density Conserva | 2012 |
Atypical femoral fracture following bisphosphonate treatment in a woman with osteogenesis imperfecta--a case report.
Topics: Aged; Alendronate; Diphosphonates; Female; Femoral Fractures; Fracture Fixation, Intramedullary; Hum | 2012 |
Alendronate treatment for infants with osteogenesis imperfecta: demonstration of efficacy in a mouse model.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Collagen Type I; Diseas | 2002 |
Fourier transform infrared imaging spectroscopy (FT-IRIS) of mineralization in bisphosphonate-treated oim/oim mice.
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Calcification, Physiologic; Disease Models, Anim | 2003 |
Alendronate affects long bone length and growth plate morphology in the oim mouse model for Osteogenesis Imperfecta.
Topics: Alendronate; Animals; Bone Development; Disease Models, Animal; Dose-Response Relationship, Drug; Fe | 2003 |
Treatment of children with Osteogenesis imperfecta in Estonia.
Topics: Administration, Oral; Adolescent; Alendronate; Bone Density; Calcitriol; Calcium Channel Agonists; C | 2003 |
Effect of treatment with alendronate in osteogenesis imperfecta type I: a case report.
Topics: Adult; Alendronate; Bone Density; Female; Fractures, Bone; Humans; Osteogenesis Imperfecta | 2004 |
Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse.
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Disease Models, Animal; Fractures, Bone; Mice; O | 2005 |
Effect of alendronate therapy in children with osteogenesis imperfecta.
Topics: Administration, Oral; Adolescent; Alendronate; Bone Density; Bone Density Conservation Agents; Child | 2005 |
Oral alendronate in osteogenesis imperfecta.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Child; Humans; Male; Osteogenes | 2005 |
Oral bisphosphonate treatment for osteogenesis imperfecta--an Indian perspective.
Topics: Administration, Oral; Alendronate; Bone Density; Bone Density Conservation Agents; Child; Child, Pre | 2007 |
Metaphyseal sclerosis associated with bisphosphonate therapy.
Topics: Alendronate; Bone and Bones; Bone Density Conservation Agents; Dermatomyositis; Diphosphonates; Huma | 2007 |
A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta.
Topics: Alendronate; Animals; Bone and Bones; Bone Development; Collagen; Disease Models, Animal; Fractures, | 2001 |